PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
Solutions to complement Company’s growing position in cell and gene therapy research and development WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene... Read more